Dr. Martina RossiPhDSelank research occupies a particular niche in neuropeptide pharmacology: the study of a small synthetic peptide developed as a stable, anxiolytic-type regulator. Selank is a synthetic heptapeptide based on the natural immunopeptide tuftsin, and much of the interest in it concerns how it interacts with GABAergic signaling and related systems in the brain. This article summarizes preclinical findings on Selank and anxiolytic peptide biology, covering its structure, the mechanisms proposed for it, and the cell and animal evidence reported so far. It states whether each finding comes from a cell or an animal model, and it describes what research has investigated rather than any outcome a reader should expect. Selank is a research compound and is not characterized here for human use.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is built from the endogenous tetrapeptide tuftsin, the short Thr-Lys-Pro-Arg fragment derived from the heavy chain of immunoglobulin G, extended at the C-terminus by three natural amino acids, Pro-Gly-Pro. That extension was added specifically to improve the molecule's metabolic stability and give it a longer duration than the rapidly degraded parent peptide. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Because it derives from tuftsin, an immunomodulatory peptide, Selank carries both neuropeptide and immune-related activities, which is part of what makes its pharmacology complex.
The link between Selank and GABAergic signaling is the most actively studied aspect of its mechanism. Working in living animals, Volkova and colleagues reported in 2016 that administration of Selank changed the mRNA levels of several genes involved in GABAergic neurotransmission in the rat frontal cortex, with the pattern of change correlating with that produced by GABA itself. The authors concluded that one of Selank's possible molecular mechanisms is allosteric modulation of the GABAergic system. This is an in vivo (rat) finding and a proposed mechanism rather than a confirmed one.[1] A follow-up study by Filatova and colleagues in 2017 tested the same question in cultured human IMR-32 neuroblastoma cells. Selank alone produced no change in the mRNA levels of the GABAergic genes studied, but when it was combined with GABA it suppressed most of the expression changes that GABA produced on its own. Taken together, these in vitro results suggest that Selank does not act directly on GABAergic gene transcription in isolated cells, but may instead modify the interaction of GABA with its receptors, which is consistent with the whole-animal effects being indirect.[2] The two studies illustrate that the GABAergic mechanism of Selank is plausible but not fully resolved.
A second, better-characterized strand concerns the endogenous opioid system. Zozulya and colleagues reported in 2001 that Selank inhibits enkephalin-degrading enzymes in vitro, dose-dependently slowing the enzymatic hydrolysis of plasma enkephalin and doing so more potently than the reference peptidase inhibitors bacitracin and puromycin.[3] By slowing enkephalin breakdown, the peptide is thought to prolong endogenous enkephalin signaling rather than acting directly on opioid receptors. Animal data support this strand. Sokolov and colleagues showed in 2002 that, in a mouse strain prone to anxiety-like behavior, Selank produced an anxiolytic-type effect in the open-field test and increased the half-life of plasma enkephalin, whereas a different strain showed neither response.[4] A further strand concerns neurotrophic signaling: Inozemtseva and colleagues reported in 2008 that intranasal Selank regulated brain-derived neurotrophic factor (BDNF) expression in the rat hippocampus in vivo, adding a neurotrophic dimension to the peptide's actions.[5] Changes in monoamine-related gene expression were also reported in the rat gene-expression work above, indicating that Selank acts across more than one neurotransmitter system.[1]
Behavioral pharmacology in rodents has characterized Selank as an anxiolytic-type compound with a profile distinct from classical sedatives. A recurring observation across preclinical studies, summarized in a 2018 review by Vyunova and colleagues, is anxiolytic-like activity without the sedation or motor impairment associated with benzodiazepines.[6] Cognitive endpoints have also been examined: Semenova and colleagues reported in 2007 that Selank affected cognitive processes in rats following early-life damage to the brain's catecholamine system.[7] These are animal model results and should not be extrapolated to human outcomes.
The directly relevant mechanistic and behavioral evidence on Selank is preclinical, drawn from cell and animal studies. Selank has been investigated in human clinical research in Russia, where a nasal formulation is registered, and the 2001 study above included a human biochemical observation: patients with generalized anxiety showed a shortened enkephalin half-life and reduced blood enkephalinase activity, the biochemical backdrop against which Selank's enzyme-inhibiting action was proposed.[3] That clinical work is distinct from the research-grade compound discussed here, and no personal outcome should be inferred from it.
Several limitations shape how this literature should be read. A large share of the work originates from a small network of affiliated Russian institutes and much of it is published in Russian-language journals, limiting independent replication. The mechanisms proposed, GABAergic, enkephalinergic, neurotrophic and monoaminergic, are multiple and not fully reconciled, and the contrast between the in vivo and in vitro GABAergic findings shows that the picture is still being worked out.
Selank is best understood as a metabolically stabilized, tuftsin-derived heptapeptide studied as an anxiolytic-type neuropeptide. Its preclinical profile points to a multi-target mechanism, with a proposed but not fully resolved action on the GABAergic system and a better-characterized effect on enkephalin-degrading enzymes, set against behavioral data in animal models. Selank is intended for laboratory research use only, and the findings above describe what has been investigated, not what any individual should expect.
Selank is available for laboratory research from Pure Peptides. View Product →
References
WRITTEN BY
Dr. Martina Rossi
PhD — Scientific Contributor and Reviewer
Dr. Martina Rossi holds a PhD from Universite Grenoble Alpes, where her doctoral research examined the vascular functions of Bone Morphogenetic Proteins in knockout mouse models. Her published work spans cell and molecular biology, vascular biology, and gene therapy, with peer-reviewed contributions appearing in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. Dr. Rossi serves as Scientific Contributor and Reviewer for the Pure Peptides research content program, independently reviewing articles for scientific accuracy.
View team profile →
An evidence-led look at Semax research into BDNF and neurotrophic signaling, covering cerebral ischemia models, enkephalin-degrading enzyme inhibition, and the peptide's clinical registration context in Russia.
